Central New York Clinical Research

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Migraine3 trials
• Type 2 diabetes2 trials

Phase

• Phase 34 trials
• Phase 2/31 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial
• Terminated1 trial

Lead sponsor

• TriGemX Bio, Inc.2 trials
• Eli Lilly and Company1 trial
• NewAmsterdam Pharma1 trial
• Pfizer1 trial

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Active, not recruiting

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· Phase 3· NewAmsterdam Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting

Closed trials

• Completed

  A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

  NCT05971940· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source